drugset / Trial / NCT01258673
A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy
Phase 3
Completed
263 enrolled
Boryung Pharmaceutical Co., Ltd
Ajou University · collabAsan Medical Center · collabCheil General Hospital and Women's Healthcare Center · collabChonbuk National University Hospital · collabChonnam National University Hospital · collabDongGuk University · collabGangnam Severance Hospital · collabHanyang University Guri Hospital · collabIlsan-Paik Hospital · collabKorea University Guro Hospital · collabKyung Hee University Hospital · collabSMG-SNU Boramae Medical Center · collabSamsung Medical Center · collabSeoul National University Bundang Hospital · collabSeoul National University Hospital · collabSeverance Hospital · collabThe Catholic University of Korea · collabYonsei University · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan/Hydrochlorothiazide combination 60/12.5mg\~120/12.5mg in patients with essential hypertension who are not controlled by fimasartan 60mg.
Timeline
- Start
- 2010-11
- Primary completion
- 2011-12
- Completion
- —
Publications
- Rhee MY, Baek SH, Kim W, Park CG, Park SW, Oh BH, Kim SH, Kim JJ, Shin JH, Yoo BS, Rim SJ, Ha JW, Doh JH, Ahn Y, Chae JK, Park JB, Kim SK, Kim CH. Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy. Drug Des Devel Ther. 2015 Jun 2;9:2847-54. doi: 10.2147/DDDT.S82098. eCollection 2015.
- Fimasartan. Am J Cardiovasc Drugs. 2011 Aug 1;11(4):249-52. doi: 10.2165/11533640-000000000-00000.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fimasartan | Small molecule | 60 mg | Oral |
| Comparator | Fimasartan | Small molecule | 120 mg | Oral |
| Subject | Hydrochlorothiazide | Unknown | 12.5 mg | — |